Page 40 - Read Online

Page 228 Peixoto et al. Cancer Drug Resist 2018;1:219-29 I http://dx.doi.org/10.20517/cdr.2018.17

within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression. J Pathol
2011;223:347-57.
3. Hirano S, Iwashita Y, Sasaki A, Kai S, Ohta M, et al. Increased mRNA expression of chemokines in hepatocellular carcinoma with
tumor-infiltrating lymphocytes. J Gastroenterol Hepatol 2007;22:690-6.
4. de la Cruz-Merino L, Barco-Sánchez A, Henao Carrasco F, Nogales Fernández E, Vallejo Benítez A, et al. New insights into the role of
the immune microenvironment in breast carcinoma. Clin Dev Immunol 2013;2013:785317.
5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
6. Allison JP. Checkpoints. Cell 2015;162:1202-5.
7. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system
and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002;99:12293-7.
8. Kelderman S, Schumacher TN, Haanen JB. Acquired and intrinsic resistance in cancer immunotherapy. Mol Oncol 2014;8:1132-9.
9. Kovacs D, Migliano E, Muscardin L, Silipo V, Catricalà C, et al. The role of Wnt/β-catenin signaling pathway in melanoma epithelial-
to-mesenchymal-like switching: evidences from patients-derived cell lines. Oncotarget 2016;7:43295-314.
10. George S, Miao D, Demetri GD, Adeegbe D, Rodig SJ, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint
Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity 2017;46:197-204.
11. Collins DC, Chenard-Poirier M, Lopez JS. The PI3K pathway at the crossroads of cancer and the immune system: strategies for next
generation immunotherapy combinations. Curr Cancer Drug Targets 2018;18:355-64.
12. Lu C, Talukder A, Savage NM, Singh N, Liu K. JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation
to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer. Oncoimmunology 2017;6:e1291106.
13. Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell
exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 2011;117:4501-10.
14. Yoneda K, Imanishi N, Ichiki Y, Tanaka F. Immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC). J UOEH
2018;40:173-89.
15. Schachter J, Ribas A, Long GV, Arance A, Grob JJ, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall
survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 2017;390:1853-62.
16. Chatwal MS, Tanvetyanon T. Malignant mesothelioma clinical trial combines immunotherapy drugs. Immunotherapy 2018;10:341-4.
17. Massari F, Santoni M, Ciccarese C, Santini D, Alfieri S, et al. PD-1 blockade therapy in renal cell carcinoma: current studies and future
promises. Cancer Treat Rev 2015;41:114-21.
18. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic
bladder cancer. Nature 2014;515:558-62.
19. Rebelatto MC, Midha A, Mistry A, Sabalos C, Schechter N, et al. Development of a programmed cell death ligand-1
immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Diagn
Pathol 2016;11:95.
20. Meyers DE, Bryan PM, Banerji S, Morris DG. Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer. Curr
Oncol 2018;25:e324-34.
21. Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase
Ib KEYNOTE-012 study. J Clin Oncol 2016;34:2460-7.
22. Hervouet E, Cheray M, Vallette FM, Cartron PF. DNA methylation and apoptosis resistance in cancer cells. Cells 2013;2:545-73.
23. Nebbioso A, Tambaro FP, Dell’Aversana C, Altucci L. Cancer epigenetics: moving forward. PLoS Genet 2018;14:e1007362.
24. Wrangle J, Wang W, Koch A, Easwaran H, Mohammad HP, et al. Alterations of immune response of non-small cell lung cancer with
azacytidine. Oncotarget 2013;4:2067-79.
25. Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, et al. Combination epigenetic therapy has efficacy in patients with refractory
advanced non-small cell lung cancer. Cancer Discov 2011;1:598-607.
26. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome
in breast cancer. J Clin Oncol 2011;29:1949-55.
27. Ovarian Tumor Tissue Analysis (OTTA) Consortium, Goode EL, Block MS, Kalli KR, Vierkant RA, et al. Dose-response association of
CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer. JAMA Oncol 2017;3:e173290.
28. Wang LX, Mei ZY, Zhou JH, Yao YS, Li YH, et al. Low dose decitabine treatment induces CD80 expression in cancer cells and
stimulates tumor specific cytotoxic T lymphocyte responses. PLoS One 2013;8:e62924.
29. Sasidharan Nair V, El Salhat H, Taha RZ, John A, Ali BR, et al. DNA methylation and repressive H3K9 and H3K27 trimethylation in
the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer. Clin Epigenetics
2018;10:78.
30. Bensaid D, Blondy T, Deshayes S, Dehame V, Bertrand P, et al. Assessment of new HDAC inhibitors for immunotherapy of malignant
pleural mesothelioma. Clin Epigenetics 2018;10:79.
31. Sasidharan Nair V, Toor SM, Taha RZ, Shaath H, Elkord E. DNA methylation and repressive histones in the promoters of PD-1, CTLA-
4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer. Clin Epigenetics 2018;10:104.
32. Röver LK, Gevensleben H, Dietrich J, Bootz F, Landsberg J, et al. PD-1 (PDCD1) promoter methylation is a prognostic factor in
patients with diffuse lower-grade gliomas harboring isocitrate dehydrogenase (IDH) mutations. EBioMedicine 2018;28:97-104.
33. Marwitz S, Scheufele S, Perner S, Reck M, Ammerpohl O, et al. Epigenetic modifications of the immune-checkpoint genes CTLA4 and
PDCD1 in non-small cell lung cancer results in increased expression. Clin Epigenetics 2017;9:51.